复发性Graves甲亢患者抗甲状腺药物治疗后的治疗选择

Q4 Medicine

中华内分泌代谢杂志 Pub Date : 2019-10-25 DOI:10.3760/CMA.J.ISSN.1000-6699.2019.10.019

Meng Liu, Jia Liu, Guang Wang

{"title":"复发性Graves甲亢患者抗甲状腺药物治疗后的治疗选择","authors":"Meng Liu, Jia Liu, Guang Wang","doi":"10.3760/CMA.J.ISSN.1000-6699.2019.10.019","DOIUrl":null,"url":null,"abstract":"Graves′ disease (GD) is the most common cause of hyperthyroidism, and its treatment includes anti-thyroid drugs (ATD), radioactive iodine therapy (RAI), and surgical treatment. ATD is the first choice for GD treatment in China, but the high recurrence rate limits its widely clinical application. The therapeutic strategy for patients with recurrent hyperthyroidism after ATD treatment is still controversial. \n \nKey words: \nHyperthyroidism; Graves′ disease; Anti-thyroid drugs; Recurrence","PeriodicalId":10120,"journal":{"name":"中华内分泌代谢杂志","volume":"35 1","pages":"903-906"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment options for patients with recurrent Graves hyperthyroidism after anti-thyroid drug treatment\",\"authors\":\"Meng Liu, Jia Liu, Guang Wang\",\"doi\":\"10.3760/CMA.J.ISSN.1000-6699.2019.10.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Graves′ disease (GD) is the most common cause of hyperthyroidism, and its treatment includes anti-thyroid drugs (ATD), radioactive iodine therapy (RAI), and surgical treatment. ATD is the first choice for GD treatment in China, but the high recurrence rate limits its widely clinical application. The therapeutic strategy for patients with recurrent hyperthyroidism after ATD treatment is still controversial. \\n \\nKey words: \\nHyperthyroidism; Graves′ disease; Anti-thyroid drugs; Recurrence\",\"PeriodicalId\":10120,\"journal\":{\"name\":\"中华内分泌代谢杂志\",\"volume\":\"35 1\",\"pages\":\"903-906\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华内分泌代谢杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1000-6699.2019.10.019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华内分泌代谢杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1000-6699.2019.10.019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

Graves病（GD）是甲状腺功能亢进症最常见的病因，其治疗包括抗甲状腺药物（ATD）、放射性碘治疗（RAI）和手术治疗。ATD是国内治疗GD的首选药物，但复发率高限制了其广泛的临床应用。ATD治疗后复发性甲状腺功能亢进患者的治疗策略仍然存在争议。关键词：甲状腺功能亢进；Graves病；抗甲状腺药物；重复

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Treatment options for patients with recurrent Graves hyperthyroidism after anti-thyroid drug treatment

Graves′ disease (GD) is the most common cause of hyperthyroidism, and its treatment includes anti-thyroid drugs (ATD), radioactive iodine therapy (RAI), and surgical treatment. ATD is the first choice for GD treatment in China, but the high recurrence rate limits its widely clinical application. The therapeutic strategy for patients with recurrent hyperthyroidism after ATD treatment is still controversial. Key words: Hyperthyroidism; Graves′ disease; Anti-thyroid drugs; Recurrence

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华内分泌代谢杂志 Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

0.60

自引率

0.00%

发文量

7243

期刊介绍： The Chinese Journal of Endocrinology and Metabolism was founded in July 1985. It is a senior academic journal in the field of endocrinology and metabolism sponsored by the Chinese Medical Association. The journal aims to be the "Chinese broadcaster of new knowledge on endocrinology and metabolism worldwide". It reports leading scientific research results and clinical diagnosis and treatment experience in endocrinology and metabolism and related fields, as well as basic theoretical research that has a guiding role in endocrinology and metabolism clinics and is closely integrated with clinics. The journal is a core journal of Chinese science and technology (a statistical source journal of Chinese science and technology papers), and is included in Chinese and foreign statistical source journal databases such as the Chinese Science and Technology Papers and Citation Database, Chemical Abstracts, and Scopus.